Curevac N.V. (NQ: CVAC )
7.360 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, Sep 26, 2023 Add to My Watchlist
All News about Curevac N.V.
CureVac Provides Update on Phase 2b/3 Trial of First-Generation COVID-19 Vaccine Candidate, CVnCoV
June 16, 2021
- Pivotal study conducted in 10 countries in fast changing environment of at least 29 COVID-19 variant strains; original strain almost completely absent - At second interim analysis, statistical...
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE /June 2, 2021 / CureVac N.V. (NASDAQ:CVAC), a global clinical-stage biopharmaceutical company developing a new class of transformative medicines based on...
CureVac's First-Generation COVID-19 Vaccine Candidate, CVnCoV, Continues Toward Phase 2b/3 Efficacy Readout in Variant-rich Environment Following DSMB Recommendation
May 28, 2021
- Study continues to progress according to protocol following first interim analysis at 59 eligible COVID-19 cases - Sequencing data to be made available in parallel with efficacy data given...
- First-Generation COVID-19 vaccine program, CVnCoV - Phase 3 trial started with CVnCoV in adults suffering from selected comorbidities - Phase 2a trial in Peru and Panama assessing third booster...